KMT2A and acute myeloid leukemia: To explore the effect of SETDB1 loss of function on AML cells, we mined data from a recent study that utilized CRISPR-Cas9 targeting of SETDB1 in the human MLL-AF9 driven AML cell line, THP-1 [58].